Major Depressive Disorder Clinical Trial
Official title:
MRI Markers of Feedback Timing During Learning in Individuals With TBI With and Without Clinical Depression
The goal of this proposal is to examine the influence of feedback timing on learning and brain function in individuals with moderate-to-severe traumatic brain injury (TBI), with and without depression.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | January 31, 2026 |
Est. primary completion date | January 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - I am between the ages of 18 and 65. - I have been diagnosed with a TBI. - I am an individual without TBI. - I am right-handed. - I have normal vision or corrected to normal vision. - I can read and speak English fluently. - I do or do not have a current diagnosis of Depression. - I am not currently pregnant. Exclusion Criteria: - I have had a neurological disease, other than TBI. - I have a significant history of alcohol or drug abuse as determined by study staff. - I have metal in my body (shrapnel, piercing that cannot be taken off, retainer on the upper jaw). - I have something in my body that restricts me from having an MRI such as: an aneurysm clip; implanted neural stimulator; implanted cardiac pacemaker or auto-defibrillator; cochlear implant (internal hearing aids); ocular foreign body (e.g. metal shavings in my eye), insulin pump or any pre- existing eye conditions (such as blurry vision, seeing double, and abnormal eye movements). - I experience discomfort in closed spaces (claustrophobia). - I have been diagnosed with a neurologic illness such as epilepsy, brain tumors, etc. (e.g. schizophrenia and bipolar disorder). - I have had corticosteroid treatment less than a month ago as determined by study staff review of my medications. - I have been informed by my doctor that is it unsafe for me to receive regular MRI as part of my medical care. |
Country | Name | City | State |
---|---|---|---|
United States | Kessler Foundation | West Orange | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Kessler Foundation | Moss Rehabilitation Research Institute, National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Learning accuracy | Participants' learning accuracy (in percent) assessed with Eprime software | Collected during the single 1 day study | |
Primary | functional MRI | Participants brain activity | Collected during the single 1 day study | |
Secondary | Verbal Paired Associates test | Verbal learning and memory assessment | Collected during the single 1 day study | |
Secondary | Logical Memory test | Verbal learning and memory assessment | Collected during the single 1 day study | |
Secondary | Delis-Kaplan Executive Function System | Executive functioning assessment | Collected during the single 1 day study | |
Secondary | Test of Premorbid Functioning | Pre-morbid cognitive and memory functioning assessment | Collected during the single 1 day study | |
Secondary | Ruff 2 & 7 Selective Attention Test | Attention Assessment | Collected during the single 1 day study | |
Secondary | Wechsler Adult Intelligence Scale, 4th edition | Working memory/processing assessment | Collected during the single 1 day study | |
Secondary | Behavioral Inhibition/Behavioral Approach Scale | Questionnaire | Collected during the single 1 day study | |
Secondary | GAD | Questionnaire | Collected during the single 1 day study | |
Secondary | PCL | Questionnaire | Collected during the single 1 day study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |